Gastric Antisecretory Drug Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
MARKET INTRODUCTION
Gastric antisecretory drugs are commonly used among patients and are often recommended to treat conditions related to gastrointestinal disease. The three antisecretory drug classes on the market include antacids, histamine H2 receptor antagonists (H2RAs), and proton pump inhibitors (PPIs). These medication classes raise gastric pH through different mechanisms and with varying durations of action: antacids are short-acting, H2RAs are intermediate-acting, and PPIs are long-acting. Antacids directly neutralize gastric acid, providing a quick onset of action and a short duration of acid suppression due to gastric emptying and gastric acid secretion.H2RAs compete reversibly with histamine at H2 receptors in gastric parietal cells to reduce gastric acid secretion. Common PPIs include omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole, with many of these being available without a prescription. PPIs irreversibly bind and inactivate the proton pump (i.e., the hydrogen/potassium adenosine triphosphatase system) at the secretory surface of gastric parietal cells. It results in suppression of gastric acid production for?>?24 h, but four days of repeated dosing is required to reach maximal effect.
MARKET DYNAMICS
The gastric antisecretory drug market has shown a significant evolution over the forecast period. The market is driven by the increasing adoption of a sedentary lifestyle, high level of stress, improper food habits, and increased use of stimulants like alcoholic beverages. Some developing countries possess issues of unhygienic water and food, which hampers the gut flora leading to gastric disorders. Genetic predisposition towards gastric ulcers is also said to propel the growth of the gastric antisecretory drug market. However, polypharmacy and drug administration without prescription have led to adverse reactions in individuals that have shown to hamper the development of this market. Moreover, long term use of antisecretory drugs, especially proton pump inhibitors, has risks associated with it like interference with vitamin b12 absorption, increased risks of super infections, osteoporosis, and many more. This as well has led to restricting the growth of this market. Technological advancements and product innovations have generated various opportunities for the gastric antisecretory market. For instance, Cadila Pharmaceuticals is the first in the world to launch a novel intravenous formulation of rabeprazole in the market, Rabeloc IV. Rabeloc IV is an intravenous Proton Pumps Inhibitor which rapidly decreases gastric acid production and intragastric pH and is used during upper gastrointestinal bleeding. Rabeloc IV has also been used to manage various conditions like severe refractory gastro-esophagus reflux disease, stress-induced mucosal injury, acute upper non-variceal bleed, upper gastrointestinal bleeding.
MARKET SCOPE
The "Gastric Antisecretory Drug Market Analysis to 2031" is a specialized and in-depth study of the pharmaceuticals in the healthcare industry with a particular focus on the global market trend analysis. This report provides an outline of the gastric antisecretory drug market with detailed market segmentation by type, application, and end-user. The gastric antisecretory drug market is expected to witness high growth during the forecast period. The report gives intricate information on the vital statistics on the market status of the leading players in the gastric antisecretory drug market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The market is segmented based on type, application, and end-user. Based on type, the market is categorized as H2- receptor antagonists, gastric proton pump inhibitors, and others. On the basis of application, the market is categorized as dyspepsia, peptic ulcer, gastro esophageal reflux, and others. Based on end-user, the market is categorized as hospitals, clinics, and others.
REGIONAL FRAMEWORK
The report lays out a detailed outline of the industry, including both quantitative and qualitative information. It gives a sketch and forecast of the gastric antisecretory drug market based on various segments. It also comprises market size and forecast estimates from the year 2020 to2028with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The gastric antisecretory drug market by each region is later subdivided into respective countries and segments. The report comprises of the analysis and forecast of 18 countries globally, along with the recent trend and opportunities prevailing in the region.
`The report analyzes factors affecting the gastric antisecretory drug market from both the demand and supply side. Further, it assesses market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. The report also consists of precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the gastric antisecretory drug market in these regions.
By Type
By Application
By End-user
MARKET PLAYERS
The report contains critical developments in the gastric antisecretory drug market as organic and inorganic growth strategies. Various firms are focusing on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions and partnerships & collaborations. These activities have led the way for the expansion of business and customer base of market players. The market players from the gastric antisecretory drug market are anticipated to have profitable growth opportunities in the coming years with the rising demand for the gastric antisecretory drug in the global market. Given below is the list of few companies engaged in the gastric antisecretory drug market.
The report also contains the profiles of key players in the gastric antisecretory drug market, along with their SWOT analysis and market strategies. Additionally, the report focuses on leading industry players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.
The Insight Partner's dedicated research and analysis team comprises of experienced professionals with advanced statistical expertise and offers various customization options in the current study.
Gastric antisecretory drugs are commonly used among patients and are often recommended to treat conditions related to gastrointestinal disease. The three antisecretory drug classes on the market include antacids, histamine H2 receptor antagonists (H2RAs), and proton pump inhibitors (PPIs). These medication classes raise gastric pH through different mechanisms and with varying durations of action: antacids are short-acting, H2RAs are intermediate-acting, and PPIs are long-acting. Antacids directly neutralize gastric acid, providing a quick onset of action and a short duration of acid suppression due to gastric emptying and gastric acid secretion.H2RAs compete reversibly with histamine at H2 receptors in gastric parietal cells to reduce gastric acid secretion. Common PPIs include omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, and rabeprazole, with many of these being available without a prescription. PPIs irreversibly bind and inactivate the proton pump (i.e., the hydrogen/potassium adenosine triphosphatase system) at the secretory surface of gastric parietal cells. It results in suppression of gastric acid production for?>?24 h, but four days of repeated dosing is required to reach maximal effect.
MARKET DYNAMICS
The gastric antisecretory drug market has shown a significant evolution over the forecast period. The market is driven by the increasing adoption of a sedentary lifestyle, high level of stress, improper food habits, and increased use of stimulants like alcoholic beverages. Some developing countries possess issues of unhygienic water and food, which hampers the gut flora leading to gastric disorders. Genetic predisposition towards gastric ulcers is also said to propel the growth of the gastric antisecretory drug market. However, polypharmacy and drug administration without prescription have led to adverse reactions in individuals that have shown to hamper the development of this market. Moreover, long term use of antisecretory drugs, especially proton pump inhibitors, has risks associated with it like interference with vitamin b12 absorption, increased risks of super infections, osteoporosis, and many more. This as well has led to restricting the growth of this market. Technological advancements and product innovations have generated various opportunities for the gastric antisecretory market. For instance, Cadila Pharmaceuticals is the first in the world to launch a novel intravenous formulation of rabeprazole in the market, Rabeloc IV. Rabeloc IV is an intravenous Proton Pumps Inhibitor which rapidly decreases gastric acid production and intragastric pH and is used during upper gastrointestinal bleeding. Rabeloc IV has also been used to manage various conditions like severe refractory gastro-esophagus reflux disease, stress-induced mucosal injury, acute upper non-variceal bleed, upper gastrointestinal bleeding.
MARKET SCOPE
The "Gastric Antisecretory Drug Market Analysis to 2031" is a specialized and in-depth study of the pharmaceuticals in the healthcare industry with a particular focus on the global market trend analysis. This report provides an outline of the gastric antisecretory drug market with detailed market segmentation by type, application, and end-user. The gastric antisecretory drug market is expected to witness high growth during the forecast period. The report gives intricate information on the vital statistics on the market status of the leading players in the gastric antisecretory drug market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The market is segmented based on type, application, and end-user. Based on type, the market is categorized as H2- receptor antagonists, gastric proton pump inhibitors, and others. On the basis of application, the market is categorized as dyspepsia, peptic ulcer, gastro esophageal reflux, and others. Based on end-user, the market is categorized as hospitals, clinics, and others.
REGIONAL FRAMEWORK
The report lays out a detailed outline of the industry, including both quantitative and qualitative information. It gives a sketch and forecast of the gastric antisecretory drug market based on various segments. It also comprises market size and forecast estimates from the year 2020 to2028with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The gastric antisecretory drug market by each region is later subdivided into respective countries and segments. The report comprises of the analysis and forecast of 18 countries globally, along with the recent trend and opportunities prevailing in the region.
`The report analyzes factors affecting the gastric antisecretory drug market from both the demand and supply side. Further, it assesses market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. The report also consists of precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the gastric antisecretory drug market in these regions.
Gastric Antisecretory Drug Market Report Analysis
Gastric Antisecretory Drug Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX Million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Takeda Pharmaceutical Company Limited
- Pfizer
- Cadila Pharmaceuticals.
- sanofi-aventis U.S. LLC
- Cipla Inc.
- Shandong Luoxin Pharmaceutical Group Stock co., ltd
- Eisai Co., Ltd
- Sandoz
- Cheplapharm Arzneimittel Gmbh
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
By Type
- H2-receptor Antagonists
- Gastric Proton Pump Inhibitors
- Others
By Application
- Dyspepsia
- Peptic Ulcer
- Gastroesophageal Reflux
- Others
By End-user
- Hospitals
- Clinics
- Others
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
The report contains critical developments in the gastric antisecretory drug market as organic and inorganic growth strategies. Various firms are focusing on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions and partnerships & collaborations. These activities have led the way for the expansion of business and customer base of market players. The market players from the gastric antisecretory drug market are anticipated to have profitable growth opportunities in the coming years with the rising demand for the gastric antisecretory drug in the global market. Given below is the list of few companies engaged in the gastric antisecretory drug market.
The report also contains the profiles of key players in the gastric antisecretory drug market, along with their SWOT analysis and market strategies. Additionally, the report focuses on leading industry players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.
- Takeda Pharmaceutical Company Limited
- Pfizer
- Cadila Pharmaceuticals.
- sanofi-aventis U.S. LLC
- Cipla Inc.
- Cheplapharm Arzneimittel Gmbh
- Shandong Luoxin Pharmaceutical Group Stock co., ltd
- Eisai Co., Ltd
- Sandoz
- SANIS
The Insight Partner's dedicated research and analysis team comprises of experienced professionals with advanced statistical expertise and offers various customization options in the current study.
Gastric Antisecretory Drug Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies
1. Takeda Pharmaceutical Company Limited
2. Pfizer
3. Cadila Pharmaceuticals.
4. sanofi-aventis U.S. LLC
5. Cipla Inc.
6. Shandong Luoxin Pharmaceutical Group Stock co., ltd
7. Eisai Co., Ltd
8. Sandoz
9. Cheplapharm Arzneimittel Gmbh
10. SANIS
1. Takeda Pharmaceutical Company Limited
2. Pfizer
3. Cadila Pharmaceuticals.
4. sanofi-aventis U.S. LLC
5. Cipla Inc.
6. Shandong Luoxin Pharmaceutical Group Stock co., ltd
7. Eisai Co., Ltd
8. Sandoz
9. Cheplapharm Arzneimittel Gmbh
10. SANIS
Get Free Sample For